Insider Selling: Twist Bioscience Corp (NASDAQ:TWST) COO Sells 22,000 Shares of Stock

Twist Bioscience Corp (NASDAQ:TWST) COO William Banyai sold 22,000 shares of Twist Bioscience stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $22.53, for a total value of $495,660.00.

William Banyai also recently made the following trade(s):

  • On Wednesday, October 16th, William Banyai sold 22,000 shares of Twist Bioscience stock. The stock was sold at an average price of $24.14, for a total value of $531,080.00.
  • On Tuesday, September 17th, William Banyai sold 22,000 shares of Twist Bioscience stock. The stock was sold at an average price of $29.86, for a total value of $656,920.00.
  • On Tuesday, August 27th, William Banyai sold 22,000 shares of Twist Bioscience stock. The stock was sold at an average price of $27.92, for a total value of $614,240.00.

NASDAQ:TWST traded down $0.47 during mid-day trading on Thursday, reaching $22.38. 2,014 shares of the company’s stock traded hands, compared to its average volume of 219,698. Twist Bioscience Corp has a 12-month low of $13.99 and a 12-month high of $35.95. The firm has a market capitalization of $718.60 million and a price-to-earnings ratio of -0.87. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.18 and a quick ratio of 6.96. The company has a 50 day moving average price of $23.10 and a 200-day moving average price of $26.54.

Several research analysts have recently commented on TWST shares. ValuEngine upgraded Twist Bioscience from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Zacks Investment Research downgraded Twist Bioscience from a “hold” rating to a “sell” rating in a report on Saturday, October 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. Twist Bioscience presently has a consensus rating of “Buy” and an average target price of $26.55.

Institutional investors have recently bought and sold shares of the business. BlackRock Inc. raised its stake in Twist Bioscience by 320.7% during the 2nd quarter. BlackRock Inc. now owns 1,532,141 shares of the company’s stock valued at $44,447,000 after buying an additional 1,167,949 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Twist Bioscience by 90.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,997,857 shares of the company’s stock worth $56,220,000 after purchasing an additional 947,399 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Twist Bioscience by 321.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,055,474 shares of the company’s stock worth $30,619,000 after purchasing an additional 805,251 shares in the last quarter. Emerald Advisers LLC increased its stake in shares of Twist Bioscience by 146.5% in the 2nd quarter. Emerald Advisers LLC now owns 579,601 shares of the company’s stock worth $16,814,000 after purchasing an additional 344,463 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust increased its stake in shares of Twist Bioscience by 156.0% in the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 524,093 shares of the company’s stock worth $15,204,000 after purchasing an additional 319,373 shares in the last quarter. 46.85% of the stock is currently owned by institutional investors and hedge funds.

Twist Bioscience Company Profile

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Featured Article: Options Trading

Insider Buying and Selling by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.